Biora Therapeutics Inc
BIOR
Get informed when a big investor buys or sells
+ FollowMarket Cap$803.63K
Close$
$-2.04
1028.4% downside
Current Fair Value
1028.4% downsideOvervalued by 1028.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $803,630.00 |
|---|---|
| Enterprise Value | $36.20 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-78.7 |
| Beta | 1.28 |
| Outstanding Shares | 3,652,862 |
Return
| Return on Equity | 29.58% |
|---|---|
| Return on Assets | -217.44% |
| Return on Invested Capital | 57.47% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.01 |
| Enterprise Value to Revenue | 20.52 |
| Enterprise Value to EBIT | -0.59 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 1.07 |
| Debt to Equity | -0.36 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 12, 2025
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.16%▲ 0.16% |
|---|---|
| Total Invested | $1,323 |
| Investors Holding | 1▲ 1.00% |
ESG Score
No data
About Progenity Inc
58 employees
CEO: Harry Stylli Biora Therapeutics, Inc. operates as a biotechnology company, primarily focused on developing innovative oral biotherapeutics. The company's core efforts include: 1. Targeted Therapeutics Program: This initiative employs an advanced, ing...